DE69633393D1 - Mitteln zur behandlung von auto-immun krankheiten - Google Patents

Mitteln zur behandlung von auto-immun krankheiten

Info

Publication number
DE69633393D1
DE69633393D1 DE69633393T DE69633393T DE69633393D1 DE 69633393 D1 DE69633393 D1 DE 69633393D1 DE 69633393 T DE69633393 T DE 69633393T DE 69633393 T DE69633393 T DE 69633393T DE 69633393 D1 DE69633393 D1 DE 69633393D1
Authority
DE
Germany
Prior art keywords
agents
agent
immune diseases
treating auto
etx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633393T
Other languages
English (en)
Other versions
DE69633393T2 (de
Inventor
Andrew Williams
Raymond Hirst
Osman Nashar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trident Pharmaceuticals Inc Boston Mass Us
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Application granted granted Critical
Publication of DE69633393D1 publication Critical patent/DE69633393D1/de
Publication of DE69633393T2 publication Critical patent/DE69633393T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69633393T 1995-07-05 1996-07-05 Mitteln zur behandlung von autoimmunkrankheiten Expired - Lifetime DE69633393T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9513733 1995-07-05
GBGB9513733.7A GB9513733D0 (en) 1995-07-05 1995-07-05 Therapeutic agents
PCT/GB1996/001614 WO1997002045A1 (en) 1995-07-05 1996-07-05 Therapeutic agents and autoimmune diseases

Publications (2)

Publication Number Publication Date
DE69633393D1 true DE69633393D1 (de) 2004-10-21
DE69633393T2 DE69633393T2 (de) 2005-11-10

Family

ID=10777189

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633393T Expired - Lifetime DE69633393T2 (de) 1995-07-05 1996-07-05 Mitteln zur behandlung von autoimmunkrankheiten

Country Status (22)

Country Link
US (1) US6287563B1 (de)
EP (1) EP0841939B1 (de)
JP (1) JP4024298B2 (de)
KR (1) KR100452000B1 (de)
CN (1) CN1313150C (de)
AT (1) ATE275968T1 (de)
AU (1) AU724516B2 (de)
CA (1) CA2225788C (de)
CZ (1) CZ298670B6 (de)
DE (1) DE69633393T2 (de)
DK (1) DK0841939T3 (de)
ES (1) ES2229276T3 (de)
GB (1) GB9513733D0 (de)
HU (1) HU224248B1 (de)
MX (1) MX9800241A (de)
NO (1) NO319747B1 (de)
NZ (1) NZ311762A (de)
PL (1) PL187266B1 (de)
PT (1) PT841939E (de)
RU (1) RU2203088C2 (de)
SI (1) SI0841939T1 (de)
WO (1) WO1997002045A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20010036917A1 (en) 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP0919243A1 (de) * 1997-11-25 1999-06-02 Duphar International Research B.V Impfstoff, dessen Adjuvant aus B-Untereinheiten des hitzelabilen Enterotoxins (LTB) von Escherichiacoli besteht
GB9800487D0 (en) * 1998-01-09 1998-03-04 Oratol Limited Therapies
GB9801871D0 (en) * 1998-01-28 1998-03-25 Univ Bristol Therapies
US7914791B1 (en) * 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
MXPA00010934A (es) * 1998-05-08 2003-07-14 Univ Bristol Vacuna.
US7041296B1 (en) 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
AU1592801A (en) * 1999-11-12 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of treating inflammatory bowel disease using cholera toxin B subunit
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CA2358061A1 (en) * 2000-09-08 2002-03-08 Stemcell Technologies Inc. Novel antibody compositions for the negative selection of specific rat leukocyte subsets
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CA2899961C (en) * 2013-02-14 2022-08-09 Cornell University Methods to protect against and treat multiple sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) * 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent

Also Published As

Publication number Publication date
MX9800241A (es) 1998-11-30
SI0841939T1 (en) 2005-04-30
KR100452000B1 (ko) 2004-11-20
GB9513733D0 (en) 1995-09-06
ES2229276T3 (es) 2005-04-16
NO980005L (no) 1998-03-05
CN1313150C (zh) 2007-05-02
NO980005D0 (no) 1998-01-02
CA2225788C (en) 2010-09-21
CA2225788A1 (en) 1997-01-23
HU224248B1 (hu) 2005-07-28
HUP9900147A2 (hu) 1999-05-28
DE69633393T2 (de) 2005-11-10
CZ298670B6 (cs) 2007-12-19
EP0841939A1 (de) 1998-05-20
HK1006496A1 (en) 1999-03-05
JP4024298B2 (ja) 2007-12-19
PT841939E (pt) 2005-02-28
PL187266B1 (pl) 2004-06-30
KR19990028578A (ko) 1999-04-15
NO319747B1 (no) 2005-09-12
ATE275968T1 (de) 2004-10-15
CN1192693A (zh) 1998-09-09
HUP9900147A3 (en) 1999-11-29
AU724516B2 (en) 2000-09-21
AU6314296A (en) 1997-02-05
NZ311762A (en) 2001-04-27
JPH11508586A (ja) 1999-07-27
CZ1298A3 (cs) 1998-06-17
DK0841939T3 (da) 2005-01-24
RU2203088C2 (ru) 2003-04-27
US6287563B1 (en) 2001-09-11
PL324424A1 (en) 1998-05-25
WO1997002045A1 (en) 1997-01-23
EP0841939B1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
ATE163195T1 (de) Lösliche liganden für cd40
ATE242960T1 (de) Vorrichtung und verfahren zur photoaktivierung
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
FR2491334B1 (de)
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE69432517D1 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
DE60013636D1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
DE69433851D1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
Wasson et al. Electrical potentials and tissue regeneration
ATE167055T1 (de) 4-guanidinobutyramid zur verbesserung des blutkreislaufs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TRIDENT PHARMACEUTICALS, INC., BOSTON, MASS., US